Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of Novel Apigenin–Piperazine Hybrids as Potent and Selective Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors for the Treatment of Cancer
Huan Long, Xiaolong Hu, Baolin Wang, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 16, pp. 12089-12108
Closed Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Recent advances in DDR (DNA damage response) inhibitors for cancer therapy
Binbin Cheng, Wei Pan, Yi Xing, et al.
European Journal of Medicinal Chemistry (2022) Vol. 230, pp. 114109-114109
Closed Access | Times Cited: 87
Poly (ADP-ribose) polymerase (PARP) inhibitors as anticancer agents: An outlook on clinical progress, synthetic strategies, biological activity, and structure-activity relationship
Pronoy Kanti Das, Gurubasavaraja Swamy Purawarga Matada, Rohit Pal, et al.
European Journal of Medicinal Chemistry (2024) Vol. 274, pp. 116535-116535
Closed Access | Times Cited: 12
Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents
Eleni Sflakidou, George Leonidis, Eirini Foroglou, et al.
Molecules (2022) Vol. 27, Iss. 19, pp. 6632-6632
Open Access | Times Cited: 29
Synthesis and anticancer mechanisms of zinc(ii)-8-hydroxyquinoline complexes with 1,10-phenanthroline ancillary ligands
Ling-Qi Du, Tianyu Zhang, Xiaomei Huang, et al.
Dalton Transactions (2023) Vol. 52, Iss. 15, pp. 4737-4751
Closed Access | Times Cited: 19
Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy
Xiaopeng Peng, Wanyi Pan, Feng Jiang, et al.
Pharmacological Research (2022) Vol. 186, pp. 106529-106529
Closed Access | Times Cited: 24
What about the progress in the synthesis of flavonoid from 2020?
Zai‐Qun Liu
European Journal of Medicinal Chemistry (2022) Vol. 243, pp. 114671-114671
Closed Access | Times Cited: 19
Design, synthesis, biological evaluation and molecular docking study of novel urea-based benzamide derivatives as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors
Guoqing Lu, Wenxing Nie, Meixiu Xin, et al.
European Journal of Medicinal Chemistry (2022) Vol. 243, pp. 114790-114790
Closed Access | Times Cited: 19
Nuclear PARP1‐Targeted Photosensitizer as a Dual‐Mode DNA‐Damaging Agent and Immune Activator for Tumor Ablation
Peixia Li, Yayin Du, Jingru Qiu, et al.
Advanced Healthcare Materials (2023) Vol. 12, Iss. 31
Closed Access | Times Cited: 12
An overview of compound properties, multiparameter optimization, and computational drug design methods for PARP-1 inhibitor drugs
Bhakti Umesh Hirlekar, Anila Nuthi, Krishan Dev Singh, et al.
European Journal of Medicinal Chemistry (2023) Vol. 252, pp. 115300-115300
Closed Access | Times Cited: 11
Advances in Development of Selective Antitumor Inhibitors That Target PARP-1
Fang Liu, Jia‐Shu Chen, Xiangqian Li, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 24, pp. 16464-16483
Closed Access | Times Cited: 11
Design, synthesis, biological evaluation of novel piperidine-based derivatives as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors
Chao Lin, Chang Liu, Panpan Hu, et al.
Bioorganic Chemistry (2024) Vol. 148, pp. 107455-107455
Closed Access | Times Cited: 4
Quinazoline-2,4(1 H,3 H)-dione Scaffold for development of a novel PARP-targeting PET probe for tumor imaging
Chunfeng He, Hui Shi, Boyu Tan, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2024) Vol. 51, Iss. 13, pp. 3840-3853
Closed Access | Times Cited: 4
Advances in the Anti-Tumor Activity of Biflavonoids in Selaginella
Mengdie Ren, Sihui Li, Qiong Gao, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 7731-7731
Open Access | Times Cited: 10
Ferroptosis Inhibitory Aromatic Abietane Diterpenoids from Ajuga decumbens and Structural Revision of Two 3,4-Epoxy Group-Containing Abietanes
Xing Peng, Qingyun Tan, Leiming Wu, et al.
Journal of Natural Products (2022) Vol. 85, Iss. 7, pp. 1808-1815
Closed Access | Times Cited: 14
Systematic Analysis and Prediction of the Target Space of Bioactive Food Compounds: Filling the Chemobiological Gaps
Andrés Sánchez-Ruiz, Gonzalo Colmenarejo
Journal of Chemical Information and Modeling (2022) Vol. 62, Iss. 16, pp. 3734-3751
Closed Access | Times Cited: 13
Small molecule tractable PARP inhibitors: Scaffold construction approaches, mechanistic insights and structure activity relationship
Amandeep Thakur, Mandeep Rana, Ritika Ritika, et al.
Bioorganic Chemistry (2023) Vol. 141, pp. 106893-106893
Closed Access | Times Cited: 7
Recent advances in structural types and medicinal chemistry of PARP-1 inhibitors
Ling Yu, Zhiwei Yan, Youde Wang, et al.
Medicinal Chemistry Research (2022) Vol. 31, Iss. 8, pp. 1265-1276
Closed Access | Times Cited: 12
Targeting selective inhibitors of PARPs in drug discovery and development
Maolin Duan, Jing Gao, Jiajin Li, et al.
Medicinal Chemistry Research (2024) Vol. 33, Iss. 10, pp. 1734-1756
Closed Access | Times Cited: 2
The synthesis and bioactivity of Apigenin derivatives
Shun Liu, Xing Zheng, Zhongqin Luo, et al.
Fitoterapia (2024) Vol. 179, pp. 106228-106228
Closed Access | Times Cited: 2
The Potential of PARP Inhibitors as Antitumor Drugs and the Perspective of Molecular Design
Yinghan Wang, Jingtao Zhang, Xiaochen Wu, et al.
Journal of Medicinal Chemistry (2024) Vol. 68, Iss. 1, pp. 18-48
Closed Access | Times Cited: 2
A multitier virtual screening of antagonists targeting PD-1/PD-L1 interface for the management of triple-negative breast cancer
HemaNandini Rajendran Krishnamoorthy, K. Ramanathan
Medical Oncology (2023) Vol. 40, Iss. 11
Closed Access | Times Cited: 6
Flavone-based dual PARP-Tubulin inhibitor manifesting efficacy against endometrial cancer
Sachin Sharma, Kavya Chandra, A. Naik, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2023) Vol. 38, Iss. 1
Open Access | Times Cited: 4
Flavone Hybrids and Derivatives as Bioactive Agents
László Hazai, Bernadett Zsoldos, Mónika Halmai, et al.
Applied Sciences (2024) Vol. 14, Iss. 3, pp. 1039-1039
Open Access | Times Cited: 1
Cytotoxicity of natural and synthetic cannabinoids and their synergistic antiproliferative effects with cisplatin in human ovarian cancer cells
Huiling Chen, Huifang Li, Jia Liu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Design, synthesis, and biological evaluation of novel 5,7,4′-trimethoxyflavone sulfonamide-based derivatives as highly potent inhibitors of LRPPRC/STAT3/CDK1
Rui Wu, Pan Li, Bingbing Hao, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107878-107878
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top